These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21126943)

  • 1. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome.
    Tarkun I; Dikmen E; Cetinarslan B; Cantürk Z
    Eur Cytokine Netw; 2010 Dec; 21(4):272-7. PubMed ID: 21126943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
    Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.
    Spanos N; Tziomalos K; Macut D; Koiou E; Kandaraki EA; Delkos D; Tsourdi E; Panidis D
    Obes Facts; 2012; 5(4):495-504. PubMed ID: 22854419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
    Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
    Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
    Luque-Ramírez M; Escobar-Morreale HF
    Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
    Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
    Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
    Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
    Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
    Pepene CE
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):119-25. PubMed ID: 21740456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma visfatin level in women with polycystic ovary syndrome.
    Dıkmen E; Tarkun I; Cantürk Z; Cetınarslan B
    Gynecol Endocrinol; 2011 Jul; 27(7):475-9. PubMed ID: 20586547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum resistin and adiponectin levels in women with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Demirci H; Oztürk C; Kan E; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2009 Apr; 25(4):246-52. PubMed ID: 19408174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
    Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
    Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome.
    Ben Ayed B; Dammak dit Mlik S; Ben Arab H; Trabelssi H; Chahtour H; Mathlouthi N; Dhuib M; Kassis M; Saiidane D; Trabelssi K; Guermazi M
    Tunis Med; 2009 Jan; 87(1):43-9. PubMed ID: 19522426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of metformin treatment on adiponectin and resistin levels in women with polycystic ovary syndrome: a prospective clinical study.
    Basios G; Trakakis E; Chrelias Ch; Panagopoulos P; Vaggopoulos V; Skarpas P; Kassanos D; Dimitriadis G; Hatziagelaki E
    Gynecol Endocrinol; 2015 Feb; 31(2):136-40. PubMed ID: 25377599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
    Ziaee A; Oveisi S; Abedini A; Hashemipour S; Karimzadeh T; Ghorbani A
    Acta Med Indones; 2012 Jan; 44(1):16-22. PubMed ID: 22451180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.